Shots:
- Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25
- Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing
- The combined entity will have 2 state of the art, FDA-approved manufacturing sites in Lincolnton, North Carolina, & Salisbury, South Australia, enhancing access to women’s health therapies globally
Ref: Businesswire | Image: Mayne Pharma
Related News:- Novartis to Acquire Anthos Therapeutics for ~$3.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
